Drug & intervention

prednisone

RxCUI 8640

Clinical trials324
Recruiting27
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Prednisone

Prednisone is a glucocorticoid medication mostly used to suppress the immune system and decrease inflammation in conditions such as asthma, COPD, and rheumatologic diseases. It is also used to treat high blood calcium due to cancer and adrenal insufficiency along with other corticosteroids. It is taken by mouth. Common side effects may include cataracts, bone loss, easy bruising, muscle weakness, and thrush. Other side effects include weight gain, swelling, high blood sugar, increased risk of infection, and psychosis. It is generally considered safe in pregnancy and low doses appear to be safe while the user is breastfeeding. After prolonged use, prednisone must be stopped gradually. Prednisone is a prodrug and must be converted to prednisolone by the liver before it becomes active. Prednisolone then binds to glucocorticoid receptors, activating them and triggering changes in gene expression. These changes inhibit function and decrease the number of key leukocytes in the bloodstream. Prednisone was patented in 1954 and approved for medical use in the United States in 1955. Prednisone is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 38th most commonly prescribed medication in the United States, with more than 15 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate CancerNCT07237269 · 2026-10-15
RECRUITING
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]NCT07802704 · 2026-09-01
RECRUITING
The CARDIOPROTECT TrialNCT07654426 · 2026-08-31
RECRUITING
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialNCT07650240 · 2026-08-04
RECRUITING
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerNCT07339267 · 2026-01-20
RECRUITING
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13
RECRUITING
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialNCT06650579 · 2025-01-31
RECRUITING
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyNCT06470243 · 2024-11-27
RECRUITING
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03
RECRUITING
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · 2024-05-20
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31
RECRUITING
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerNCT06173362 · 2023-11-09
RECRUITING
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasNCT05389423 · 2023-06-27
RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14
RECRUITING
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerNCT04947254 · 2021-08-05
RECRUITING
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerNCT04729114 · 2021-06-14
RECRUITING
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaNCT04139304 · 2021-05-24
RECRUITING
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerNCT04734730 · 2021-05-04
RECRUITING
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerNCT04633252 · 2021-02-23
RECRUITING
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerNCT03819296 · 2021-02-21
RECRUITING
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyNCT04175431 · 2020-09-30
RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesNCT04300556 · 2020-08-06
RECRUITING
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate CancerNCT03833921 · 2019-05-23
RECRUITING
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · 2018-09-24
RECRUITING
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis PlaquesNCT02784210 · 2016-10-05
RECRUITING
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent AsthmaNCT00576069 · 2007-10-25
RECRUITING
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNCT07852195 · 2027-01-06
NOT_YET_RECRUITING
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")NCT07649304 · 2026-10-09
NOT_YET_RECRUITING
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 · 2026-07-30
ENROLLING_BY_INVITATION
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair AlterationsNCT06392841 · 2025-10-01
WITHDRAWN
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate CancerNCT06527690 · 2025-04-30
WITHDRAWN
DOSE Trial: Optimal Dose of Oral Corticosteroids to Treat Asthma ExacerbationsNCT06833814 · 2025-02-17
NOT_YET_RECRUITING
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant AbirateroneNCT06384222 · 2024-12-09
ACTIVE_NOT_RECRUITING
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate CancerNCT06329830 · 2024-10-01
WITHDRAWN
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)NCT06566989 · 2024-09-19
COMPLETED
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.NCT06500247 · 2024-07-31
NOT_YET_RECRUITING
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)NCT06554639 · 2024-07-11
COMPLETED
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene MutationsNCT05689021 · 2024-03-05
TERMINATED
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 · 2023-09-28
COMPLETED

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.